Test Price
900 AED✅ Home Collection Available
HLA-B*38 Genotyping Test in UAE | 900 AED | 2026 DHA Guidelines
تحليل التنميط الجيني HLA-B*38 في الإمارات | 900 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Molecular Processing (Cert: INT/EGQ/2509DA/3139).
- ✓Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Transport & VIP Mobile Phlebotomy (8 AM–11 PM, 7 Days).
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance for Result Interpretation by DHA-Licensed Clinical Team.
- ✓Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
الملخص التنفيذي: يُعد فحص التنميط الجيني لـ HLA-B*38 اختباراً تشخيصياً جزيئياً متطوراً يُستخدم لتحديد وجود الأليل HLA-B*38 المرتبط بعدد من الاضطرابات المناعية الذاتية الجلدية والروماتيزمية. يُجرى التحليل في مختبر معتمد دولياً بشهادة ISO 9001:2015 مع ضمان حساسية تشخيصية تصل إلى 99.9%، ويتضمن خدمة سحب دم منزلي فاخرة وفق معايير سلسلة التبريد المعتمدة، واستشارة طبية هاتفية لتفسير النتائج، والتحقق الفوري من تغطية التأمين الصحي عبر تطبيق واتساب على الرقم +971545488731.
Overview
The HLA-B*38 Genotyping Test is a high-resolution molecular assay that identifies the presence of the HLA-B*38 allele, a genetic marker strongly associated with autoimmune skin and rheumatologic conditions including psoriatic arthritis, ankylosing spondylitis, and psoriasis. This test employs Reverse Sequence-Specific Oligonucleotide Probe (SSOP) technology on the Luminex platform, delivering allele-level precision essential for differential diagnosis and personalized treatment planning.
اختبار HLA-B*38 هو فحص جيني عالي الدقة يُحدد الأليل المرتبط بأمراض المناعة الذاتية الجلدية والمفصلية، ويُستخدم لتوجيه التشخيص وخطة العلاج الشخصية.
| Feature | Our HLA-B*38 Genotyping Test | Standard Serological HLA Typing |
|---|---|---|
| Methodology | Reverse SSOP – Luminex (Molecular, High Resolution) | Microlymphocytotoxicity (Serological, Low Resolution) |
| Precision | Allele-Level Discrimination (B*38:01, B*38:02, etc.) | Broad Antigen Group Only (B38) |
| Turnaround Time | 10–12 Working Days | 14–21 Working Days |
| Sample Transport | ISO-Certified Cold-Chain Monitored | Ambient Transport |
| Clinical Utility | Disease Association, Pharmacogenomic Guidance | Transplant Compatibility Only |
Physician Insight & Safety Protocol
"A positive HLA-B*38 result offers a meaningful genetic clue, but it does not, in isolation, confirm or exclude any specific diagnosis — your full clinical picture, including symptom history, physical examination, and complementary laboratory markers, must guide the final interpretation. I have seen many patients find clarity and direction when this genetic insight is thoughtfully integrated into a comprehensive rheumatologic or dermatologic evaluation, and I want you to feel supported every step of the way. Please know that our clinical team is always available to walk you through what your results mean for your unique health journey."
— Dr. PRABHAKAR REDDY, DHA License No. 61713011, Consultant Clinical Pathologist
⚠ Medication Warning:
Do not discontinue any prescribed immunosuppressive, anti-inflammatory, biologic, or disease-modifying antirheumatic drug (DMARD) without consulting your treating physician. Abrupt cessation of these medications may precipitate serious disease flares, organ damage, or systemic complications entirely independent of your genetic test results. This test does not assess medication efficacy or safety.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed):
- Whole blood transfusion within the preceding 14 days (may cause chimerism and erroneous genotyping).
- Active hemodilution or large-volume intravenous fluid resuscitation within 24 hours.
- Inability to obtain adequate venous access after two attempts by a certified phlebotomist.
- Severe anemia (Hemoglobin < 7 g/dL) requiring urgent clinical stabilization prior to elective genetic testing.
- Known coagulopathy or therapeutic anticoagulation at supratherapeutic levels (INR > 3.5).
Emergency Red Flags — Seek Immediate Medical Attention:
- Sudden-onset vision loss, eye pain, photophobia, or floaters (possible acute anterior uveitis — strongly associated with HLA-B*38-linked spondyloarthropathies).
- Acute severe joint swelling with high fever and inability to bear weight (possible septic arthritis requiring urgent intervention).
- New-onset widespread pustular skin eruption with systemic symptoms including fever and malaise (possible generalized pustular psoriasis — a medical emergency).
- Chest pain with dyspnea and pleuritic discomfort in a patient with known autoimmune disease.
Patient FAQ & Clinical Guidance
1. What is the HLA-B*38 test used for in the UAE, and which conditions are linked to this genetic marker?
The HLA-B*38 genotyping test is primarily utilized to identify genetic susceptibility to psoriatic arthritis, ankylosing spondylitis, psoriasis vulgaris, and certain autoimmune uveitis syndromes by detecting the specific HLA-B*38 allele through high-resolution molecular analysis of your DNA from a standard whole blood sample. This test assists dermatologists, rheumatologists, and general physicians in the UAE in narrowing differential diagnoses when a patient presents with overlapping joint and skin symptoms that remain clinically ambiguous, enabling earlier targeted intervention and specialist referral where indicated.
يُستخدم اختبار التنميط الجيني HLA-B*38 لتحديد القابلية الوراثية للإصابة بالتهاب المفاصل الصدفي والتهاب الفقار المقسط والصدفية والتهاب العنبية المناعي الذاتي، وذلك عبر الكشف عن الأليل المحدد من خلال تحليل جزيئي عالي الدقة لعينة الدم.
2. Do I need to fast or stop any medications before taking the HLA-B*38 blood test?
No fasting or dietary restriction is required before the HLA-B*38 genotyping test, and you should continue all your prescribed medications unless explicitly instructed otherwise by your treating physician, because this is a constitutional genetic test that analyzes your inherited DNA sequence which remains unaffected by food intake, hydration status, or circulating drug metabolites. The test requires only 4 mL of whole blood collected in an EDTA (Lavender Top) tube or alternatively 6 mL in an ACD (Yellow Top) tube, shipped under refrigerated cold-chain conditions without freezing, ensuring complete sample integrity throughout transport to our ISO-accredited molecular laboratory.
لا يتطلب اختبار HLA-B*38 أي صيام أو تحضيرات خاصة، ويجب الاستمرار في تناول الأدوية الموصوفة ما لم ينصح الطبيب بخلاف ذلك، لأن التحليل الجيني لا يتأثر بالطعام أو الأدوية.
3. How accurate and reliable is the HLA-B*38 genotyping test compared to older HLA typing methods?
The Reverse SSOP-Luminex methodology used in our HLA-B*38 genotyping test delivers 99.9% diagnostic sensitivity with allele-level resolution that distinguishes specific B*38 subtypes (e.g., B*38:01 from B*38:02), far surpassing the accuracy of older serological microlymphocytotoxicity assays which can only identify broad antigen groups with significantly higher ambiguity and cross-reactivity errors. Our ISO 9001:2015 certified facility employs multiplexed fluorescent bead-based detection with automated allele-calling software validated against the most current 2026 IPD-IMGT/HLA reference database, ensuring that every result meets the rigorous reproducibility standards required for clinical decision-making in the UAE healthcare system.
يتميز اختبار HLA-B*38 بتقنية SSOP-Luminex بدقة تشخيصية تبلغ 99.9% مع تمييز على مستوى الأليل، متفوقاً بذلك على الطرق المصلية القديمة، ويُجرى في مختبر معتمد ISO 9001:2015 وفق أحدث قواعد بيانات HLA العالمية.
UAE Regulatory Compliance: This diagnostic service complies with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 provisions applicable to minors, and the UAE Personal Data Protection Law (PDPL) for genetic data privacy. Facility License No. 9834453. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
ICD-10-CM Codes (2026): M07.9 (Psoriatic Arthritis, Unspecified), M45.9 (Ankylosing Spondylitis, Unspecified), Z84.89 (Family History of Other Specified Conditions — Genetic Susceptibility to Autoimmune Disease).
LOINC: 80776-8 — HLA-B Typing by Molecular Genetics Method.
Methodology: Reverse Sequence-Specific Oligonucleotide Probe (SSOP) — Luminex Platform. Specimen: 4 mL whole blood in EDTA (Lavender Top) or 6 mL in ACD (Yellow Top), shipped refrigerated. DO NOT FREEZE. TAT: 10–12 Working Days. Price: 900 AED.
Clinical Specialists: Dermatologist, Rheumatologist, General Physician. This must be interpreted in conjunction with complete clinical evaluation.
Contact & Home Collection: WhatsApp +971 54 548 8731 | Home Collection Available Daily 8 AM – 11 PM across all Emirates.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians